Imunon, Inc. (IMNN) Stock

Imunon, Inc., a pioneering clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey, specializes in advancing DNA-based immunotherapies, vaccines, and targeted chemotherapies. Established in 1982 and formerly known as Celsion Corporation until September 2022, Imunon is dedicated to developing and commercializing innovative treatments. The company's diverse product pipeline includes GEN-1, a DNA-based immunotherapy designed for localized treatment in ovarian cancer patients. Additionally, Imunon is advancing ThermoDox, a proprietary heat-activated formulation of liposomal doxorubicin, aimed at various cancer indications.

Imunon stands out with its cutting-edge platform technologies in the feasibility stage, focused on advancing nucleic acid-based immunotherapies, vaccines, and other DNA or RNA therapies for anti-cancer applications. These technologies underscore Imunon's commitment to leveraging scientific innovation to address unmet medical needs across oncology. By harnessing the power of genetic and immunological research, Imunon aims to redefine treatment paradigms and improve outcomes for patients globally.

Headquartered in Lawrenceville, New Jersey, Imunon operates at the forefront of biotechnological advancement. The company's strategic focus on DNA-based therapies and its robust research capabilities position it strongly in the competitive landscape of biopharmaceuticals. Imunon continues to forge ahead with its mission to pioneer transformative therapies that hold promise for the future of cancer treatment.